Supported by the experimental data, we demonstrated the clinical significance of TBL1X and Flot2 as biomarkers of NPC metastasis, which supports their high targeted therapeutic value for NPC patients. The gene discussed is TBL1X; the disease is nasopharyngeal carcinoma.